Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment

Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment

Abstract Background Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a therapy approved for cystic fibrosis (CF) that has given improved clinical outcomes in patients carrying the F508del mutation. There are few published data regarding ETI’s effects on patients’ quality of life (QoL). This study aims to (...

Full description

Saved in:
Bibliographic Details
Main Authors: Buniotto Francesca, Tridello Gloria, De Scolari Antonella, Meneghelli Ilaria, Pintani Emily, Perobelli Sandra, Cipolli Marco
Format: Article
Language:English
Published: SpringerOpen 2025-05-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Quality of life
CFQ-R
Cystic fibrosis
(Highly effective) modulator
ETI (Elezacaftor-Ivacaftor-Tezacaftor)
Long-term treatment benefits
Online Access:https://doi.org/10.1186/s41687-025-00879-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41687-025-00879-0

Similar Items